Story Stocks^®

RadNet (RDNT) is looking pretty rad to investors today following its Q1 report this morning. Shares are trading nicely higher despite the diagnostic imaging company reporting a larger adjusted loss than expected. Investors are instead focusing on revenue growing 22.1% yr/yr, marking RDNT's strongest quarterly growth rate in the past five years, to $575.6 mln, which was well above expectations. RDNT also raised FY26 revenue and adjusted EBITDA guidance for its Imaging Center segment.

• Severe winter weather across the Northeast during January and February negatively impacted revenue and Adjusted EBITDA, but the business rebounded strongly in March.
• Aggregate advanced imaging growth, including MRI, CT, and PET/CT, climbed 19.7%, while same-center advanced imaging growth was +8.2%. Advanced imaging represented 29.3% of procedural volume in Q1 compared to 26.9%. Investors are reacting positively to the improving procedure mix because advanced imaging carries higher margins than routine imaging.
• RDNT continues building out its DeepHealth segment, the company's AI and radiology-informatics division focused on integrating imaging workflows, cloud infrastructure, and clinical AI models. In March 2026, RDNT acquired Paris-based radiology AI company Gleamer, significantly expanding DeepHealth's clinical AI portfolio across imaging modalities.
• RDNT estimates that by year-end, over 70% of RadNet studies could run through clinical AI tools, while all radiologist reports are expected to be processed through DeepHealth's Reporting Pro AI-powered summarization engine.

Briefing.com Analyst Insight:

Investors are clearly looking past RDNT's EPS miss and focusing instead on the company's accelerating revenue growth, raised FY26 guidance, improving imaging mix, and expanding DeepHealth opportunity. The stock has struggled in recent months as investors shifted from viewing RadNet as a steady imaging-center operator toward treating it more like a higher-risk AI growth story. Today's report helped restore some confidence that the company's AI investments may be driving tangible operational and financial benefits. The key debate going forward remains whether DeepHealth can evolve into a genuinely scalable radiology AI platform or if it ultimately proves to be more of a value-added extension of the core imaging-center business.